<DOC>
	<DOC>NCT01548014</DOC>
	<brief_summary>The purpose was to evaluate as to whether administration of infliximab of 12 week interval with supplementary VSL#3 is more effective or at least of similar efficacy when compared to conventional administration of infliximab only of 8 week interval.</brief_summary>
	<brief_title>The Effect of a Probiotic Preparation (VSL#3) Plus Infliximab in Children With Crohn's Disease</brief_title>
	<detailed_description>The purpose of our study was to evaluate if supplementation of VSL#3 can improve treatment outcome for those pediatric Crohn's patients treated with infliximab every 12 weeks.</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Pediatric patients who were diagnosed with severe Crohn's disease who require infliximab treatment confirmed diagnostic of Crohn's disease in clinical, endoscopic and histological findings patients who has proven to have infliximab antibody</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Crohn's disease</keyword>
	<keyword>VSL #3</keyword>
	<keyword>infliximab</keyword>
</DOC>